即时诊断市场－全球产业规模、份额、趋势、机会及预测（按产品、平台、购买模式、最终用户、地区和竞争格局划分，2021-2031年）

全球照护现场诊断市场预计将从 2025 年的 498.9 亿美元成长到 2031 年的 848.3 亿美元，复合年增长率为 9.25%。

该市场定义为在患者附近进行、无需依赖中心检查室基础设施即可快速获得结果的医学检测。其主要驱动力是全球慢性病和感染疾病的日益增多，这些疾病需要即时做出临床决策以改善患者预后。此外，对分散式医疗服务的需求不断增长，也推动了这些诊断解决方案在非医院环境（例如居家医疗保健和远距诊所）的普及。

然而，由于严格的法规结构，包括高昂的合规成本和漫长的产品商业化週期，市场面临许多挑战。这种复杂的核准流程对寻求引进新技术的製造商构成了巨大的财务障碍。例如，根据欧洲医疗技术协会（MedTech Europe）报告，到2024年，根据体外诊断医疗设备法规，品管系统认证的平均成本将达到108,307欧元。这些不断上涨的营运成本可能会限制小规模诊断设备开发商的进入，从而扼杀创新并阻碍​​市场扩张。

市场驱动因素

微流体和生物感测器技术的进步正在从根本上改变全球照护现场诊断市场，使患者能够在床边直接进行检查室层级的分子检测。这些创新能够以高灵敏度快速检测复杂病原体，从而减少对集中式基础设施的依赖，并加速治疗启动。自动化平台的整合尤其迅速增长，这主要得益于对可在传统医院实验室之外部署的精准呼吸系统诊断的需求。例如，丹纳赫公司旗下的Sepede部门在其2024年第三季公布财报上报告称，其呼吸系统诊断产品创造了4.25亿美元的收入，凸显了先进分子技术在维持市场成长势头方面发挥的关键作用。

此外，全球慢性病和感染疾病率上升是市场扩张的主要驱动力，亟需获得及时的临床洞察以减轻严重的健康后果。随着糖尿病等慢性病日益普遍，患者越来越依赖持续监测解决方案来辅助自我管理，并减轻急诊机构的负担。值得注意的是，雅培在「2024年第三季财报」新闻稿中指出，持续血糖监测系统的广泛应用推动了该公司糖尿病护理部门19.1%的有机销售额成长。罗氏的情况更为明显，其诊断部门2024年的销售额以固定外汇计算成长了4%，反映出全球对免疫诊断和临床化学检测的持续需求。

市场挑战

严格的法律规范是全球照护现场诊断市场成长的主要障碍，因为它们会带来高昂的合规成本并延缓产品商业化进程。这些严格的核准流程要求製造商投入大量资源进行全面的临床试验和编写详细的技术文檔，从而占用了原本可用于研发的资金。沉重的合规负担显着延长了新检测方案的上市时间，延迟了产生收入，并造成了瓶颈，这对缺乏足够流动资金来应对长期无收入期的中小型开发商尤为不利。

这些监管障碍的影响显而易见，它们减缓了创新和市场准入的步伐。面对难以预测的认证时间表，製造商常常推迟或取消在关键地区的产品上市，这直接阻碍了市场扩张。根据欧洲医疗技术协会（MedTech Europe）预测，到2024年，这些实施方面的挑战将导致领先的体外诊断设备製造商选择欧盟作为其主要上市地区的意愿下降40%。这项数据表明，新型诊断设备的普及率明显下降，证实了过度监管要求正在限制基本医疗检测的普及，并减缓整体市场成长。

市场趋势

整合人工智慧 (AI) 和机器学习的自动化结果解读技术正在显着推动全球照护现场诊断市场的发展，其显着提升了诊断准确性并简化了临床工作流程。这些技术被整合到诊断平台中，以实现复杂生物数据的自动化分析，最大限度地减少人为错误，并使非专业人员能够在分散式环境中执行进阶检测。监管方面的进步也为这项技术变革提供了支持。正如 MedTech Dive 在 2024 年 10 月报导的那样，截至 2024 年 8 月，美国食品药物管理局(FDA)核准了950 种搭载人工智慧或机器学习技术的医疗设备，使製造商能够部署提供即时临床决策支援的智慧工具。

同时，零售诊所和药局就地检验的日益普及正在改变医疗服务模式，在传统医院体系之外建立了一条便捷的「检测即治疗」路径。大型连锁药局正积极拓展服务范围，将基层医疗诊所和诊断中心直接整合到其零售门市网路中，以满足消费者对便利性就诊服务的需求。这一策略转变正在推动财务成长。根据沃博联（Walgreens Boots Alliance）2024财年财报，该公司美国医疗保健部门第四季营收达21亿美元，较去年同期成长7.1%。这印证了消费者对能够提供即时检测结果并与后续医疗服务无缝衔接的分散式检查点的偏好。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球即时诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（血糖监测产品、心血管代谢监测产品、传染病检查产品、凝血监测产品、COVID-19 检测产品、其他）
  • 依平台分类（横向流动化验、试纸条检测、微流体、分子诊断、免疫检测）
  • 按购买方式（处方笺药、非处方药）
  • 依最终使用者（医院/诊所、门诊手术中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美即时诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲即时诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区即时诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲即时诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲即时诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球即时诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• EKF Diagnostics
• Abbott Laboratories Inc.
• Siemens Healthineers Ag
• F. Hoffmann-La Roche Ltd
• Quidel Corporation
• Danaher Corporation
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc
• Biomerieux SA
• Chembio Diagnostics, Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Point of Care Diagnostics Market is projected to expand from USD 49.89 Billion in 2025 to USD 84.83 Billion by 2031, registering a compound annual growth rate of 9.25%. Defined as medical testing conducted near the patient to deliver rapid results independent of central laboratory infrastructure, this market is primarily driven by the increasing global prevalence of chronic and infectious diseases that require immediate clinical decision-making to improve patient outcomes. Furthermore, the rising demand for decentralized healthcare services supports the widespread adoption of these diagnostic solutions in non-hospital environments, such as home care settings and remote clinics.

However, the market confronts significant challenges due to stringent regulatory frameworks that mandate high compliance costs and prolong product commercialization. These complex approval processes establish substantial financial barriers for manufacturers attempting to introduce new technologies. For instance, MedTech Europe reported that in 2024, the average fee for Quality Management System certification under the In Vitro Diagnostic Regulation was 108,307 euros. Such elevated operational expenses can stifle innovation and hinder market expansion by restricting the participation of smaller diagnostic developers.

Market Driver

Technological advancements in microfluidics and biosensors are fundamentally transforming the Global Point of Care Diagnostics Market by facilitating laboratory-quality molecular testing directly at the patient's bedside. These innovations enable the rapid detection of complex pathogens with high sensitivity, reducing dependence on centralized infrastructure and accelerating treatment initiation. The integration of automated platforms has seen a particular surge, driven by the need for precise respiratory diagnostics deployable outside traditional hospital labs; for example, Danaher Corporation's Cepheid division reported in its 'Third Quarter 2024 Earnings Release' that respiratory product diagnostics generated $425 million in revenue, highlighting the critical role of advanced molecular technologies in maintaining market momentum.

Additionally, the rising global incidence of chronic and infectious diseases acts as a primary catalyst for market expansion, necessitating immediate clinical insights to mitigate severe health outcomes. As chronic conditions like diabetes escalate, there is a growing reliance on continuous monitoring solutions that empower patient self-management and relieve pressure on emergency facilities. Notably, Abbott's 'Abbott Reports Third-Quarter 2024 Results' press release indicated that sales in its Diabetes Care division grew by 19.1 percent on an organic basis due to the widespread adoption of continuous glucose monitoring systems. This demand for effective disease management tools is further evidenced by Roche, where Diagnostics Division sales increased by 4 percent at constant exchange rates in 2024, reflecting sustained global demand for immunodiagnostic and clinical chemistry testing.

Market Challenge

Stringent regulatory frameworks impose substantial compliance costs and delay product commercialization, presenting a formidable obstacle to the growth of the Global Point of Care Diagnostics Market. These rigorous approval processes require manufacturers to allocate extensive resources to comprehensive clinical trials and detailed technical documentation, diverting capital away from research and development. This heavy compliance burden significantly extends the time-to-market for new testing solutions, creating a bottleneck that postpones revenue generation and discourages investment in novel technologies, particularly affecting smaller developers who lack the liquidity to endure prolonged non-revenue periods.

The impact of these regulatory hurdles is evident in the reduced pace of innovation and market entry. Faced with unpredictable certification timelines, manufacturers often delay or cancel product launches in key regions, which directly stalls market expansion. According to MedTech Europe, the preference for the European Union as a primary launch geography dropped by 40% among large in vitro diagnostic manufacturers in 2024 due to these implementation challenges. This statistic demonstrates a clear contraction in the deployment of new diagnostics, confirming that excessive regulatory demands are actively restricting the availability of essential medical testing and dampening overall market growth.

Market Trends

The integration of Artificial Intelligence and Machine Learning for Automated Result Interpretation is significantly advancing the Global Point of Care Diagnostics Market by improving diagnostic accuracy and streamlining clinical workflows. These technologies are increasingly embedded in diagnostic platforms to automate the analysis of complex biological data, minimizing human error and enabling non-specialized personnel to perform sophisticated testing in decentralized settings. This technological shift is supported by regulatory momentum; as noted by MedTech Dive in October 2024, the U.S. Food and Drug Administration had authorized a cumulative total of 950 AI or machine learning-enabled medical devices by August 2024, allowing manufacturers to deploy smart tools that provide real-time clinical decision support.

Simultaneously, the rising utilization of point-of-care testing in retail clinics and pharmacies is transforming healthcare delivery by establishing accessible "test-to-treat" pathways outside of traditional hospital infrastructure. Major pharmacy chains are aggressively expanding their service portfolios, integrating primary care clinics and diagnostic hubs directly into their retail footprints to capture the demand for convenient, walk-in medical services. This strategic pivot is yielding financial growth; according to the Walgreens Boots Alliance 'Fiscal Year 2024 Earnings' report, the company's U.S. Healthcare segment generated fourth-quarter sales of $2.1 billion, a 7.1 percent increase over the prior year, underscoring consumer preference for decentralized testing locations that offer immediate results and seamless connections to treatment.

Key Market Players

• EKF Diagnostics
• Abbott Laboratories Inc.
• Siemens Healthineers Ag
• F. Hoffmann-La Roche Ltd
• Quidel Corporation
• Danaher Corporation
• Becton, Dickinson and Company
• Thermo Fisher Scientific Inc
• Biomerieux S.A.
• Chembio Diagnostics, Inc

Report Scope

In this report, the Global Point of Care Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point of Care Diagnostics Market, By Product

• Glucose Monitoring Products
• Cardiometabolic Monitoring Products
• Infectious Disease Testing Products
• Coagulation Monitoring products
• Covid-19 Test Products
• Others

Point of Care Diagnostics Market, By Platform

• Lateral Flow Assays
• Dipsticks
• Microfluidics
• Molecular Diagnostics
• Immunoassays

Point of Care Diagnostics Market, By Mode Of Purchase

• Prescription Based Products
• OTC Products

Point of Care Diagnostics Market, By End User

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Point of Care Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point of Care Diagnostics Market.

Available Customizations:

Global Point of Care Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point of Care Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Glucose Monitoring Products, Cardiometabolic Monitoring Products, Infectious Disease Testing Products, Coagulation Monitoring products, Covid-19 Test Products, Others)
  • 5.2.2. By Platform (Lateral Flow Assays, Dipsticks, Microfluidics, Molecular Diagnostics, Immunoassays)
  • 5.2.3. By Mode Of Purchase (Prescription Based Products, OTC Products)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Point of Care Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Platform
  • 6.2.3. By Mode Of Purchase
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Point of Care Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Platform
      • 6.3.1.2.3. By Mode Of Purchase
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Point of Care Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Platform
      • 6.3.2.2.3. By Mode Of Purchase
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Point of Care Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Platform
      • 6.3.3.2.3. By Mode Of Purchase
      • 6.3.3.2.4. By End User

7. Europe Point of Care Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Platform
  • 7.2.3. By Mode Of Purchase
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Point of Care Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Platform
      • 7.3.1.2.3. By Mode Of Purchase
      • 7.3.1.2.4. By End User
  • 7.3.2. France Point of Care Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Platform
      • 7.3.2.2.3. By Mode Of Purchase
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Point of Care Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Platform
      • 7.3.3.2.3. By Mode Of Purchase
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Point of Care Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Platform
      • 7.3.4.2.3. By Mode Of Purchase
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Point of Care Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Platform
      • 7.3.5.2.3. By Mode Of Purchase
      • 7.3.5.2.4. By End User

8. Asia Pacific Point of Care Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Platform
  • 8.2.3. By Mode Of Purchase
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Point of Care Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Platform
      • 8.3.1.2.3. By Mode Of Purchase
      • 8.3.1.2.4. By End User
  • 8.3.2. India Point of Care Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Platform
      • 8.3.2.2.3. By Mode Of Purchase
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Point of Care Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Platform
      • 8.3.3.2.3. By Mode Of Purchase
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Point of Care Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Platform
      • 8.3.4.2.3. By Mode Of Purchase
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Point of Care Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Platform
      • 8.3.5.2.3. By Mode Of Purchase
      • 8.3.5.2.4. By End User

9. Middle East & Africa Point of Care Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Platform
  • 9.2.3. By Mode Of Purchase
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Point of Care Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Platform
      • 9.3.1.2.3. By Mode Of Purchase
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Point of Care Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Platform
      • 9.3.2.2.3. By Mode Of Purchase
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Point of Care Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Platform
      • 9.3.3.2.3. By Mode Of Purchase
      • 9.3.3.2.4. By End User

10. South America Point of Care Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Platform
  • 10.2.3. By Mode Of Purchase
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Point of Care Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Platform
      • 10.3.1.2.3. By Mode Of Purchase
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Point of Care Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Platform
      • 10.3.2.2.3. By Mode Of Purchase
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Point of Care Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Platform
      • 10.3.3.2.3. By Mode Of Purchase
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Point of Care Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. EKF Diagnostics
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc.
• 15.3. Siemens Healthineers Ag
• 15.4. F. Hoffmann-La Roche Ltd
• 15.5. Quidel Corporation
• 15.6. Danaher Corporation
• 15.7. Becton, Dickinson and Company
• 15.8. Thermo Fisher Scientific Inc
• 15.9. Biomerieux S.A.
• 15.10. Chembio Diagnostics, Inc

16. Strategic Recommendations

17. About Us & Disclaimer